17,607 results match your criteria glp-1 receptor


A Real-World Comparison of Cardiovascular, Medical and Costs Outcomes in New Users of SGLT2 Inhibitors versus GLP-1 Agonists.

Diabetes Res Clin Pract 2021 Apr 9:108800. Epub 2021 Apr 9.

Humana Healthcare Research, Inc., Humana Inc., Louisville, KY.

Aims: To compare SGLT2 inhibitors and GLP-1 agonists on cardiovascular (CV) outcomes, treatment persistence/discontinuation, healthcare utilization and costs.

Methods: This retrospective cohort study utilized medical and pharmacy claims to identify new SGLT2 inhibitor or GLP-1 agonist users from January 2015 to June 2017. A total of 5,507 patients were included in each treatment group after 1:1 propensity score matching. Read More

View Article and Full-Text PDF

Diabetes, insulin and new therapeutic strategies for Parkinson's disease: focus on glucagon-like peptide-1 receptor agonists.

Front Neuroendocrinol 2021 Apr 9:100914. Epub 2021 Apr 9.

Laboratory of Cellular and Molecular Neurobiology of Parkinson's disease, Research Center for Molecular Medicine and Chronic Diseases (CIMUS), IDIS, University of Santiago de Compostela, Santiago de Compostela, Spain; Networking Research Center on Neurodegenerative Diseases (CiberNed), Spain.

Parkinson's disease and diabetes mellitus are two chronic disorders associated with aging that are becoming increasingly prevalent worldwide. Parkinson is a multifactorial progressive condition with no available disease modifying treatments at the moment. Over the last few years there is growing interest in the relationship between diabetes (and impaired insulin signaling) and neurodegenerative diseases, as well as the possible benefit of antidiabetic treatments as neuroprotectors, even in non-diabetic patients. Read More

View Article and Full-Text PDF

Evaluation of glucagon-like peptide-1 receptor expression in non-diabetic and diabetic atherosclerotic mice using PET tracer Ga-NODAGA-exendin-4.

Am J Physiol Endocrinol Metab 2021 Apr 12. Epub 2021 Apr 12.

Turku PET Centre, University of Turku, Finland.

Activation of glucagon-like peptide-1 receptor (GLP-1R) signaling attenuates development of atherosclerosis and vascular inflammation. However, the expression of GLP-1R in atherosclerotic arteries remains uncertain. We evaluated whether a positron emission tomography (PET) tracer Ga-NODAGA-exendin-4 enables detection and imaging of GLP-1R expression in the mouse atherosclerotic aorta. Read More

View Article and Full-Text PDF

Developing GLP-1 Conjugated Self-Assembling Nanofibers Using Copper-Catalyzed Alkyne-Azide Cycloaddition and Evaluation of Their Biological Activity.

Bioconjug Chem 2021 Apr 12. Epub 2021 Apr 12.

School of Pharmacy, The University of Queensland, Woolloongabba 4102, Australia.

Glucagon-like peptide-1 GLP-1 is a gut-derived peptide secreted from pancreatic β-cells that reduces blood glucose levels and body weight; however, native GLP-1 (GLP-1(7-36)-NH and GLP-1(7-37)) have short circulation half-lives (∼2 min) due to proteolytic degradation and rapid renal clearance due to its low molecular weight (MW; 3297.7 Da). This study aimed to improve the proteolytic stability and delivery properties of glucagon-like peptide-1 (GLP-1) through modifications that form nanostructures. Read More

View Article and Full-Text PDF

Effects of long-acting analogues of lamprey GLP-1 and paddlefish glucagon on alpha- to beta-cell transdifferentiation in an insulin-deficient transgenic mouse model.

J Pept Sci 2021 Apr 11:e3328. Epub 2021 Apr 11.

Diabetes Research Group, School of Biomedical Sciences, Ulster University, Cromore Road, Coleraine, BT52 1SA, UK.

The abilities of the long-acting, dual-agonist anti-diabetic peptides [D-Ala ]palmitoyl-lamprey GLP-1 and [D-Ser ]palmitoyl-paddlefish glucagon to induce α-cell to β-cell transdifferentiation were investigated in Glu ;ROSA26-eYFP mice. These animals have been genetically engineered so that yellow fluorescent protein is specifically expressed in glucagon-producing α-cells, thereby allowing cell lineage tracing. Insulin deficiency was produced by treatment of the mice with multiple low doses of streptozotocin. Read More

View Article and Full-Text PDF

New antidiabetic therapy and HFpEF: light at the end of tunnel?

Heart Fail Rev 2021 Apr 11. Epub 2021 Apr 11.

Clinica Medica, University of Milan-Bicocca, Milan, Italy.

New antidiabetic therapy that includes sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor (GLP-1R) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors showed significant benefit on cardiovascular outcomes in patients with and without type 2 diabetes mellitus, and this was particularly confirmed for SGLT2 inhibitors in subjects with heart failure (HF) with reduced ejection fraction (HFrEF). Their role on patients with HF with preserved ejection fraction (HFpEF) is still not elucidated, but encouraging results coming from the clinical studies indicate their beneficial role. The role of GLP-1R agonists and particularly DPP-4 inhibitors is less clear and debatable. Read More

View Article and Full-Text PDF

Safety and efficacy of pharmacologic weight loss in patients with cirrhosis.

Obes Sci Pract 2021 Apr 2;7(2):159-167. Epub 2020 Dec 2.

Division of Gastroenterology and Hepatology Scripps Clinic La Jolla California USA.

Background: Obesity poses unique risks in patients with advanced liver fibrosis; however, given surgical risks of bariatric surgery in cirrhosis treatment recommendations are currently limited to lifestyle interventions. This study seeks to inform a potential treatment gap by describing the safety and efficacy of pharmacologic weight loss in patients with advanced liver disease.

Methods: A retrospective chart review of the electronic medical record was conducted for all patients in the Scripps Health system from 2005 to 2017 with established advanced liver fibrosis that were prescribed medications associated with weight loss. Read More

View Article and Full-Text PDF

Ex vivo normothermic perfusion of isolated segmental porcine bowel: a novel functional model of the small intestine.

BJS Open 2021 Mar;5(2)

Department of Surgery, University of Cambridge, and NIHR Cambridge Biomedical Research Campus, Cambridge, UK.

Background: There is an unmet need for suitable ex vivo large animal models in experimental gastroenterology and intestinal transplantation. This study details a reliable and effective technique for ex vivo normothermic perfusion (EVNP) of segmental porcine small intestine.

Methods: Segments of small intestine, 1. Read More

View Article and Full-Text PDF

GLP-1 peptide analogs for targeting pancreatic beta cells.

Drug Discov Today 2021 Apr 8. Epub 2021 Apr 8.

Department of Microbiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. Electronic address:

Loss or dysfunction of the pancreatic beta cells or insulin receptors leads to diabetes mellitus (DM). This usually occurs over many years; therefore, the development of methods for the timely detection and clinical intervention are vital to prevent the development of this disease. Glucagon-like peptide-1 receptor (GLP-1R) is the receptor of GLP-1, an incretin hormone that causes insulin secretion in a glucose-dependent manner. Read More

View Article and Full-Text PDF

Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey.

Can J Diabetes 2021 Feb 24. Epub 2021 Feb 24.

Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address:

Objectives: Optimal control of cardiovascular risk factors in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD) is challenging. Limited data are available from the primary care setting on achievement of guideline-recommended targets in this population before the use of sodium-glucose cotransporter protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists.

Methods: The Diabetes Mellitus Status in Canada survey included 5,172 patients with T2D seen by primary care physicians (PCPs) in November 2012. Read More

View Article and Full-Text PDF
February 2021

Direct Effect of the Synthetic Analogue of Glucagon-Like Peptide Type 1, Liraglutide, on Mature Adipocytes Is Realized through Adenylate-Cyclase-Dependent Enhancing of Insulin Sensitivity.

Biochemistry (Mosc) 2021 Mar;86(3):350-360

Institute of Experimental Cardiology, National Medical Research Centre for Cardiology, Moscow, 121552, Russia.

Incretin hormones analogues, including glucagon-like peptide type 1 (GLP-1), exhibit complex glucose-lowering, anorexigenic, and cardioprotective properties. Mechanisms of action of GLP-1 and its analogues are well known for pancreatic β-cells, hepatocytes, and other tissues. Nevertheless, local effects of GLP-1 and its analogues in adipose tissue remain unclear. Read More

View Article and Full-Text PDF

High-Fat Diet Drives an Aggressive Pancreatic Cancer Phenotype.

J Surg Res 2021 Apr 7;264:163-172. Epub 2021 Apr 7.

Department of Surgery, Charleston, South Carolina; Department of Hollings Cancer Center, Charleston, South Carolina; Department of Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, South Carolina. Electronic address:

Background: Emerging evidence indicates associations between high-fat diet (HFD), metabolic syndrome (MetS), and increased risk of pancreatic cancer. However, individual components of an HFD that increase cancer risk have not been isolated. In addition, a specific pattern of cytokine elevation by which MetS drives pancreatic tumor progression is not well described. Read More

View Article and Full-Text PDF

Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.

Diabetes Ther 2021 Apr 10. Epub 2021 Apr 10.

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ, 08536, US.

Introduction: The superior efficacy and safety of semaglutide once-weekly (QW), compared with dulaglutide, liraglutide, or exenatide QW, have been demonstrated in the SUSTAIN trials. This study assessed treatment persistence and adherence to semaglutide QW versus dulaglutide, liraglutide, or exenatide QW in a real-world setting.

Methods: This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D) initiating semaglutide QW, dulaglutide, liraglutide, or exenatide QW between January 1, 2018 and April 30, 2019. Read More

View Article and Full-Text PDF

Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: a meta-analysis of randomized controlled trials.

Br J Clin Pharmacol 2021 Apr 9. Epub 2021 Apr 9.

Universidad Autonoma de Nuevo Leon, Department of Orthopedics and Traumatology, University Hospital "Dr. José E. González", School of Medicine, Monterrey, NL, México.

Aim: Previous studies have reported an elevation in adiponectin concentrations using glucagon-like peptide-1 receptor agonists (GLP-1 RA) therapy; however, this possible pleiotropic effect is still uncertain. Thus, the objective of this meta-analysis of randomized controlled trials was to assess the impact of GLP-1 RA on adiponectin levels.

Methods: This systematic review and meta-analysis included randomized controlled trials investigating the effect of GLP-1 RA on circulating adiponectin concentrations. Read More

View Article and Full-Text PDF

Experimental Evidence that (-)-Epicatechin and Anthocyanins Modulate Glucagon-Like Peptide-1 Metabolism: Relevant For Humans?

J Nutr 2021 Apr 8. Epub 2021 Apr 8.

Department of Nutritional Sciences, King's College London, London, United Kingdom.

View Article and Full-Text PDF

Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses.

Heart 2021 Apr 8. Epub 2021 Apr 8.

Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada

Objective: To inform a clinical practice guideline (BMJ Rapid Recommendations) considering sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists for treatment of adults with type 2 diabetes, we summarised the available evidence regarding the performance of validated risk models on cardiovascular and kidney outcomes in these patients.

Methods: We systematically searched bibliographic databases in January 2020 to identify observational studies evaluating risk models for all-cause and cardiovascular mortality, heart failure (HF) hospitalisations, end-stage kidney disease (ESKD), myocardial infarction (MI) and ischaemic stroke in ambulatory adults with type 2 diabetes. Using a random effects model, we pooled discrimination measures for each model and outcome, separately, and descriptively summarised calibration plots, when available. Read More

View Article and Full-Text PDF

Molecular mechanisms of lipotoxicity-induced pancreatic β-cell dysfunction.

Int Rev Cell Mol Biol 2021 12;359:357-402. Epub 2021 Mar 12.

Department of Molecular Biophysics, Biofisika Institute (University of Basque Country and Consejo Superior de Investigaciones Científicas (UPV/EHU, CSIC)), Leioa, Spain; Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), Leioa, Spain. Electronic address:

Type 2 diabetes (T2D), a heterogeneous disorder derived from metabolic dysfunctions, leads to a glucose overflow in the circulation due to both defective insulin secretion and peripheral insulin resistance. One of the critical risk factor for T2D is obesity, which represents a global epidemic that has nearly tripled since 1975. Obesity is characterized by chronically elevated free fatty acid (FFA) levels, which cause deleterious effects on glucose homeostasis referred to as lipotoxicity. Read More

View Article and Full-Text PDF

Molecular mechanisms of β-cell dysfunction and death in monogenic forms of diabetes.

Int Rev Cell Mol Biol 2021 23;359:139-256. Epub 2021 Mar 23.

ULB Center for Diabetes Research (UCDR), Université Libre de Bruxelles, Brussels, Belgium. http://www.ucdr.be/. Electronic address:

Monogenetic forms of diabetes represent 1%-5% of all diabetes cases and are caused by mutations in a single gene. These mutations, that affect genes involved in pancreatic β-cell development, function and survival, or insulin regulation, may be dominant or recessive, inherited or de novo. Most patients with monogenic diabetes are very commonly misdiagnosed as having type 1 or type 2 diabetes. Read More

View Article and Full-Text PDF

Appetite and Energy Intake Regulation in Response to Acute Exercise.

Med Sci Sports Exerc 2021 Apr 7. Epub 2021 Apr 7.

Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO Department of Health and Kinesiology, College of Health, University of Utah, Salt Lake City, UT Anschutz Health & Wellness Center at the University of Colorado, Anschutz Medical Campus, Aurora, CO Division of General Internal Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, UT Division of Geriatric Medicine, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO Rocky Mountain Regional Veterans Administration, Aurora, CO.

Purpose: To determine if energy intake and appetite regulation differ in response to an acute bout of resistance exercise (REx) vs aerobic exercise (AEx).

Methods: Physically inactive adults (n=24, 35±2% body fat, 50% female) completed 3 conditions: AEx (walking at 65-70% heart rate max for 45 minutes); REx (1-set to failure of 12 exercises); and sedentary control (SED). Each condition was initiated in the post-prandial state (35 minutes post breakfast). Read More

View Article and Full-Text PDF

Exenatide twice daily plus glargine vs. aspart 70/30 twice daily in type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin.

Endocr Pract 2021 Apr 5. Epub 2021 Apr 5.

Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address:

Background: Many type 2 diatetic patients treated with premixed insulin gradually have inadequate glycaemic control and switch to a basal-bolus regimen, which raises some concerns for weight gain and increased hypoglycaemic risk. Switching to combination use of glp-1 agonist and basal insulin may be an alternative option.

Methods: After a 12-week premixed human insulin 70/30 dosage optimization period, 200 patients with HbA1c of 7. Read More

View Article and Full-Text PDF

Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: a Pilot Randomized Controlled Trial.

Nicotine Tob Res 2021 Apr 8. Epub 2021 Apr 8.

Center for Neurobehavioral Research on Addiction, Louis A. Faillace, M.D., Department of Psychiatry and Behavioral Sciences, UTHealth, McGovern Medical School, Houston, TX.

Introduction: Approved pharmacological treatments for smoking cessation are modestly effective, underscoring the need for improved pharmacotherapies. Glucagon-like peptide-1 receptor (GLP-1R) agonists attenuate the rewarding effects of nicotine in preclinical studies. We examined the efficacy of extended-release exenatide, a GLP-1R agonist, combined with nicotine replacement therapy (NRT, patch) for smoking cessation, craving and withdrawal symptoms, with post-cessation body weight as secondary outcome. Read More

View Article and Full-Text PDF

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials.

Diabetes Obes Metab 2021 Apr 8. Epub 2021 Apr 8.

Department of Diabetes & Endocrinology, Morriston Hospital, Swansea Bay University Health Board, Swansea.

Aims: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) have cardiorenal protective properties in patients with type 2 diabetes (T2DM) that are not fully understood. Inflammation and oxidative stress play a role in the pathogenesis of T2DM and its associated cardiorenal complications. Anti-inflammatory and antioxidant properties may contribute towards explaining the beneficial effects of GLP-1RAs. Read More

View Article and Full-Text PDF

Obesity therapeutics: The end of the beginning.

Cell Metab 2021 Apr;33(4):705-706

WT-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK. Electronic address:

Obese non-diabetic patients receiving semaglutide, an injectable long-acting GLP-1 receptor agonist, in a large randomized placebo-controlled trial, lost and maintained ∼15% of their body weight for over a year (Wilding et al., 2021). This impressive result is likely to usher in a new era of anti-obesity drugs based on hormones that suppress food intake, largely through acting on the brain. Read More

View Article and Full-Text PDF

Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity.

J Med Chem 2021 Apr 7. Epub 2021 Apr 7.

Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122 Wuxi, China.

Hapten-specific endogenous antibodies are naturally occurring antibodies present in human blood. Herein, we investigated a new strategy in which small-molecule haptens were utilized as naturally occurring antibody binders for peptide half-life extension. The glucagon-like peptide 1 receptor agonist exendin 4 was site-specifically functionalized with the dinitrophenyl (DNP) hapten at the C-terminus via sortase A-mediated ligation. Read More

View Article and Full-Text PDF

Use of GLP1RAs and occurrence of respiratory disorders: a meta-analysis of large randomized trials of GLP1RAs.

Clin Respir J 2021 Apr 7. Epub 2021 Apr 7.

Department of Respiratory Medicine, Second Affiliated Hospital of KunMing Medical University, KunMing, 650101, China.

Objectives: No large sample studies have been designed to evaluate the efficacy of glucagon-like peptide-1 receptor agonists (GLP1RAs) in the primary and secondary prevention of respiratory disorders. We aimed at evaluating the relationship between use of GLP1RAs and occurrence of 12 kinds of respiratory disorders.

Methods: Large randomized placebo-controlled trials of GLP1RAs were included. Read More

View Article and Full-Text PDF

Targeting cellular senescence prevents glucocorticoid-induced bone loss through modulation of the DPP4-GLP-1 axis.

Signal Transduct Target Ther 2021 Apr 7;6(1):143. Epub 2021 Apr 7.

Department of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

View Article and Full-Text PDF

Improved Postprandial Glucose Metabolism in Type 2 Diabetes by Dual Glucagon-like Peptide-1 / Glucagon Receptor Agonist SAR425899 in Comparison to Liraglutide.

Diabetes Obes Metab 2021 Apr 6. Epub 2021 Apr 6.

Department of Information Engineering, University of Padova, Padova, Italy.

Objective: Dual glucagon-like peptide-1/glucagon receptor agonist (GLP-1/GCG RA) SAR425899 showed positive effects on glycemic control and reduction of body weight in overweight to obese patients with type 2 diabetes mellitus (T2D) after 4 weeks of treatment, with a safety profile comparable with GLP-1 RA. Here, we aim to give further insights into SAR425899 efficacy, by also providing direct comparison against the GLP-1 RA Liraglutide in terms of key parameters of glucose metabolism.

Research Design And Methods: Seventy overweight to obese subjects with T2D were randomized to receive once-daily subcutaneous administrations of SAR425899 (0. Read More

View Article and Full-Text PDF

Metabolic responses and benefits of GLP-1 receptor ligands.

Br J Pharmacol 2021 Apr 6. Epub 2021 Apr 6.

Diabetes Research Group, Ulster University, Coleraine, Co., Londonderry, BT52 1SA, Northern Ireland.

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has undergone a revolutionary turnaround from discovery to clinically approved therapeutic. Rapid progress in drug design and formulation has led from initial development of short- and long-acting drugs suitable for daily or weekly parenteral administration, respectively, through to the most recent approval of an orally active GLP-1 agent. The current review outlines the biological action profile of GLP-1 including the various beneficial metabolic responses in pancreatic and extrapancreatic tissues, including the gastrointestinal tract, liver, bone and kidney as well as the reproductive cardiovascular and central nervous systems. Read More

View Article and Full-Text PDF

GLP-1 receptor agonists: fighting obesity with an eye to cardiovascular risk.

Eur Heart J 2021 Apr 2. Epub 2021 Apr 2.

Department of Cardiovascular and Pulmonary Science, Fondazione Policlinico A. Gemelli-IRCSS, Catholic University of the Sacred Heart, Rome, Italy.

View Article and Full-Text PDF

Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice.

Nat Microbiol 2021 Apr 5. Epub 2021 Apr 5.

Department of Environmental Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, Korea.

The gut microbiota, which includes Akkermansia muciniphila, is known to modulate energy metabolism, glucose tolerance, immune system maturation and function in humans. Although A. muciniphila is correlated with metabolic diseases and its beneficial causal effects were reported on host metabolism, the molecular mechanisms involved have not been identified. Read More

View Article and Full-Text PDF